The Role of Thalidomide in Reversing Cachexia in Patients with Oesophageal Cancer

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

ISRCTN

Registry ID

ISRCTN23944748

Enrollment

Registered

2006-06-06

Start date

2002-12-10

Completion date

Unknown

Last updated

2015-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Oesophageal cancer Cancer Oesophageal cancer

Interventions

Thalidomide versus placebo

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Adults with non-obstructing and inoperable oesophageal cancer (dysphagia score <3, able to swallow a semi-solid diet)

Exclusion criteria

Exclusion criteria: 1. Pre-menopausal women 2. Patients receiving any adjuvant chemotherapy or radiotherapy 3. Patients with oesophageal obstruction 4. Those with established neuropathy 5. Patients requiring frequent laser ablation sessions 6. Those unable to maintain an adequate caloric intake 7. Increased debility

Design outcomes

Primary

Measure	Time frame
Change in lean body mass	—

Secondary

Measure	Time frame
1. Change in resting energy expenditure 2. Change in total body weight	—

Countries

United Kingdom

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026